REGENXBIO (NASDAQ:RGNX) Shares Gap Down – Here’s What Happened

REGENXBIO Inc. (NASDAQ:RGNX)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $13.41, but opened at $9.60. REGENXBIO shares last traded at $11.0250, with a volume of 3,306,818 shares traded.

REGENXBIO News Roundup

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on RGNX shares. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday. Leerink Partners boosted their price objective on shares of REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Wall Street Zen upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Finally, Royal Bank Of Canada boosted their target price on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

REGENXBIO Stock Down 3.8%

The firm has a market capitalization of $564.95 million, a P/E ratio of -3.22 and a beta of 1.07. The business’s 50-day simple moving average is $13.74 and its 200 day simple moving average is $11.29.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The company had revenue of $29.73 million during the quarter, compared to analysts’ expectations of $24.41 million. Sell-side analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Institutional Trading of REGENXBIO

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC grew its holdings in shares of REGENXBIO by 2,247.7% in the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after purchasing an additional 594,161 shares during the last quarter. Jane Street Group LLC grew its holdings in REGENXBIO by 151.1% in the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after acquiring an additional 249,156 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in REGENXBIO by 78.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 30,630 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 13,458 shares during the last quarter. CWM LLC increased its position in shares of REGENXBIO by 75.4% in the second quarter. CWM LLC now owns 46,816 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 20,120 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of REGENXBIO during the second quarter valued at about $1,453,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.